Alnylam Europe Ag.

Cambridge, MA, United States

Alnylam Europe Ag.

Cambridge, MA, United States

Time filter

Source Type

Patent
Alnylam Pharmaceuticals, Alnylam Europe Ag. and The Regents Of The University Of California | Date: 2014-01-29

The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a mutant Epidermal Growth Factor Receptor (EGFR), and methods of using the dsRNA to inhibit expression of mutant EGFR.


Patent
Alnylam Europe Ag. and Scripps Research Institute | Date: 2011-12-07

The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a human Aha gene in a cell, wherein said dsRNA comprises at least two sequences that are complementary to each other and wherein a sense strand comprises a first sequence and an antisense strand comprises a second sequence comprising a region of complementarity which is fully complementary to at least a part of an mRNA encoding an Aha gene or forms one, two, three or four mismatched base pairs upon hybridization to said part of an mRNA, and wherein said region of complementarity is less than 30 nucleotides in length and wherein the dsRNA effects cleavage of an mRNA encoding an Aha gene within the target sequence of a second dsRNA having a sense strand of SEQ ID NO: 5 and an antisense strand of SEQ ID NO: 6, said antisense strand being complementary to the latter sense strand.

Loading Alnylam Europe Ag. collaborators
Loading Alnylam Europe Ag. collaborators